Search details
1.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Article
in English
| MEDLINE | ID: mdl-36265087
2.
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCE.
Transfusion
; 64(2): 223-235, 2024 02.
Article
in English
| MEDLINE | ID: mdl-38323704
3.
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
Br J Haematol
; 201(4): 645-652, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36794878
4.
Cognitive and adaptive behaviors associated with disease severity and genotype in patients with mucopolysaccharidosis II.
Mol Genet Metab
; 140(3): 107652, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37506513
5.
Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Haematologica
; 108(11): 2946-2958, 2023 11 01.
Article
in English
| MEDLINE | ID: mdl-36951168
6.
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.
Haematologica
; 108(2): 532-542, 2023 02 01.
Article
in English
| MEDLINE | ID: mdl-35979720
7.
Diversity of Participation in Clinical Trials and Influencing Factors: Findings from the Health Information National Trends Survey 2020.
J Gen Intern Med
; 38(4): 961-969, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36138277
8.
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis.
Eur J Haematol
; 110(6): 618-625, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36732677
9.
Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia.
Acta Haematol
; 146(5): 366-372, 2023.
Article
in English
| MEDLINE | ID: mdl-37315549
10.
Short-term and long-term financial toxicity from breast cancer treatment: a qualitative study.
Support Care Cancer
; 32(1): 24, 2023 Dec 14.
Article
in English
| MEDLINE | ID: mdl-38095729
11.
Therapeutic plasma exchange in alloimmune platelet refractoriness.
Transfus Apher Sci
; 62(6): 103782, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37550092
12.
Clinical implementation of genetic testing in adults for hereditary hematologic malignancy syndromes.
Genet Med
; 24(11): 2367-2379, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36112138
13.
Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
Mol Genet Metab
; 137(1-2): 127-139, 2022.
Article
in English
| MEDLINE | ID: mdl-36027721
14.
Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
Mol Genet Metab
; 137(1-2): 92-103, 2022.
Article
in English
| MEDLINE | ID: mdl-35961250
15.
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Blood
; 136(6): 674-683, 2020 08 06.
Article
in English
| MEDLINE | ID: mdl-32285126
16.
The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes.
Ann Hematol
; 101(5): 1023-1030, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35190844
17.
A 17-gene stemness score for rapid determination of risk in acute leukaemia.
Nature
; 540(7633): 433-437, 2016 12 15.
Article
in English
| MEDLINE | ID: mdl-27926740
18.
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
Br J Haematol
; 194(2): 319-324, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34060069
19.
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Haematologica
; 106(1): 56-63, 2021 01 01.
Article
in English
| MEDLINE | ID: mdl-31896684
20.
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Curr Oncol Rep
; 23(10): 120, 2021 08 04.
Article
in English
| MEDLINE | ID: mdl-34350512